Robert F. Garry

ii. The COI Committee determined that Dr. Garry’s financial interest related to Zalgen Labs could directly and significantly affect the conduct and reporting of the research. As the Principal Investigator, Dr. Garry has plenary oversight responsibility for the grant project. As Tulane University’s PI, he will have responsibility for project administration, including subcontractor management and scientific publications. He will work closely with scientists at the Sanford Burnham Prybus Medical Discovery Institute, The Scripps Research Institute (TRSI), The University of Texas Medical Branch at Galveston and Zalgen Labs to ensure that the Milestones of the grant are fully achieved, ultimately resulting in design of novel LASV glycoproteins that rapidly elicit broadly protective immune responses against current antigenically diverse lineages of the virus. Zalgen Labs will be directly involved in engineering the recombinant VSV LASV G variants as proposed in the application to NIH. Zalgen will also lend expertise to implementation of binding assays and viral entry inhibition platforms to support product release. Zalgen will perform aspects of cell culture scale-up activities and purification of recombinant VSV for testing as vaccine candidates. The COI Committee determined that data collection and evaluation at various points of the project could be affected by Dr. Garry’s financial interests.